Blood Cancer Journal - Table of Contents alert Volume 6 December 2016

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 6, December 2016 In this issue Review Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders. Explore the benefits of submitting your next research article. Review Top The role of the proteasome in AML C M Csizmar, D-H Kim and Z Sachs Blood Cancer J 2016 6: e503; 10.1038/bcj.2016.112 Abstract | Full Text Original Articles Top A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival C Botta, M T Di Martino, D Ciliberto, M Cucè, P Correale, M Rossi, P Tagliaferri and P Tassone Blood Cancer J 2016 6: e511; 10.1038/bcj.2016.118 Abstract | Full Text Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era R Chakraborty, E Muchtar, S K Kumar, D Jevremovic, F K Buadi, D Dingli, A Dispenzieri, S R Hayman, W J Hogan, P Kapoor, M Q Lacy, N Leung and M A Gertz Blood Cancer J 2016 6: e512; 10.1038/bcj.2016.117 Abstract | Full Text Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study A Desjonquères, P Chevallier, X Thomas, F Huguet, T Leguay, M Bernard, J-O Bay, E Tavernier, A Charbonnier, F Isnard, M Hunault, P Turlure, M Renaud, J-N Bastié, C Himberlin, S Lepretre, B Lioure, V Lhéritier, V Asnafi, K Beldjord, M Lafage-Pochitaloff, M C Béné, N Ifrah and H Dombret on behalf of the French Group for Research in Adult ALL (GRAALL) Blood Cancer J 2016 6: e504; 10.1038/bcj.2016.111 Abstract | Full Text Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial J R Jones, D A Cairns, W M Gregory, C Collett, C Pawlyn, R Sigsworth, A Striha, R Henderson, M F Kaiser, M Jenner, G Cook, N H Russell, C Williams, G Pratt, B Kishore, J Lindsay, M T Drayson, F E Davies, K D Boyd, R G Owen, G H Jackson and G J Morgan on behalf of the NCRI Haemato-Oncology CSG Blood Cancer J 2016 6: e506; 10.1038/bcj.2016.114 Abstract | Full Text The complexity of interpreting genomic data in patients with acute myeloid leukemia A Nazha, A Zarzour, K Al-Issa, T Radivoyevitch, H E Carraway, C M Hirsch, B Przychodzen, B J Patel, M Clemente, S R Sanikommu, M Kalaycio, J P Maciejewski and M A Sekeres Blood Cancer J 2016 6: e510; 10.1038/bcj.2016.115 Abstract | Full Text Letters to the Editor Top MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia K Krowiorz, J Ruschmann, C Lai, M Ngom, T Maetzig, V Martins, A Scheffold, E Schneider, N Pochert, C Miller, L Palmqvist, A Staffas, M Mulaw, S R Bohl, C Buske, M Heuser, J Kraus, K O'Neill, C L Hansen, O I Petriv, H Kestler, H Döhner, L Bullinger, K Döhner, R K Humphries, A Rouhi and F Kuchenbauer Blood Cancer J 2016 6: e508; 10.1038/bcj.2016.110 Full Text Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis B Li, P Zhang, G Feng, Z Xu, T Qin, Y Zhang, Z Sha, D Dong, H Zhang, L Fang, L Pan, N Hu, S Qu, W Cai, G Huang and Z Xiao Blood Cancer J 2016 6: e505; 10.1038/bcj.2016.116 Full Text Uncovering molecular abnormalities leading to the Warburg effect in primary refractory diffuse large B-cell lymphoma M Soleja, M Mims and G Rivero Blood Cancer J 2016 6: e502; 10.1038/bcj.2016.104 Full Text Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia' W H Tong Blood Cancer J 2016 6: e509; 10.1038/bcj.2016.119 Abstract | Full Text Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis S Weber, T Haferlach, C Haferlach and W Kern Blood Cancer J 2016 6: e507; 10.1038/bcj.2016.120 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.